REMERON SolTab 30mg price in UAE

Overview

Welcome to Dwaey, specifically on REMERON SolTab 30mg Tablets/Orodispersible page.
This medicine contains an important and useful components, as it consists of Mirtazapine.
REMERON SolTab 30mg is available in the market in concentration 30mg/Tablet and in the form of Tablets/Orodispersible.

N.V. ORGANON is the producer of REMERON SolTab 30mg and it is imported from NETHERLANDS, The most popular alternatives of REMERON SolTab 30mg are listed downward .

Mode Of Action

Mirtazapine, a piperazinoazepine tetracyclic antidepressant, enhances noradrenergic and serotonergic activity through blockade of central presynaptic adrenergic ?2-receptors.

Indication

Depression
Major depressive disorder

Precaution

Epilepsy or history of seizures; avoid completely in unstable cases. Hepatic or renal impairment, cardiac disorders e.g. conduction disturbances, angina pectoris, recent MI. Hypotension, DM, psychoses, history of bipolar disorder. Stop treatment if jaundice develops. Micturition disturbances, angle-closure glaucoma, raised intraocular pressure. Monitor patient for signs of bone marrow depression. Monitor patient for suicidal tendency. Avoid abrupt withdrawal. May impair ability to drive or operate machinery. Pregnancy and lactation. Elderly. Lactation: Avoid

Side Effects

>10% Somnolence (54%)
Weight gain (>7% increase in <49% of pediatric patients)
Xerostomia (25%)
Increased appetite (17%)
Constipation (13%) 1-10% Asthenia (8%)
lWeakness (8%)
Weight gain (>7% increase in 8% of adults)
Dizziness (7%)
Serum TGs increased (6%)
Dream disorder (4%)
Disturbance in thinking (3%)
ALT increased (2%)
Peripheral edema (2%)
Myalgia (2%)
Confusion (2%)
Urinary frequency (2%)
Tremor (2%)
Back pain (2%)
Dyspnea (1%) <1% Mania (0.2%)
Grand mal seizure (less than 0.1%) Frequency Not Defined Depression exacerbation
Status epilepticus
Suicidal thoughts
suicide (rare)
Agranulocytosis
Neutropenia

Contra indication

Mirtazapine Tablets are contraindicated in patients with a known hypersensitivity to mirtazapine or to any of the excipients.

Pregnancy and lactation

Pregnancy category: C

Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks

Interaction

Potentiation of sedative effects with alcohol or benzodiazepines. Increased plasma levels with potent CYP3A4 inhibitors (e.g. HIV-protease inhibitors, azole antifungals including ketoconazole, erythromycin, nefazodone). Reduced plasma levels with carbamazepine and other inducers of CYP3A4. Increased bioavailability with cimetidine. Potentially Fatal: Do not use with or within 2 wk of stopping an MAOI; at least 1 wk should elapse between discontinuing mirtazapine and initiating any drug which may provoke a serious reaction (e.g. phenelzine).